Shevelev V I, Kanorskiĭ S G
Kardiologiia. 2012;52(7):56-60.
We compared efficacy and safety of warfarin, direct thrombin inhibitor dabigatran and clopidogrel in prevention of stroke in 210 patients with nonvalvular atrial fibrillation (AF) aged 65-80 years. The use of dabigatran (110 mg twice daily) for 12 months or warfarin was associated with similar rate of ischemic stroke but caused less bleeding (2.8 vs. 16.9%, p<0.05). Treatment with clopidogrel prevented stroke no less successfully, than those with warfarin and dabigatran and turned out to be sufficiently safe. When chosing antithrombotic therapy in gerontological patients with nonvalvular AF dabigatran and clopidogrel can be considered acceptable alternative to warfarin.
我们比较了华法林、直接凝血酶抑制剂达比加群和氯吡格雷在210例年龄在65至80岁的非瓣膜性心房颤动(AF)患者中预防中风的疗效和安全性。使用达比加群(每日两次,每次110毫克)12个月或华法林,缺血性中风发生率相似,但出血较少(2.8%对16.9%,p<0.05)。氯吡格雷治疗预防中风的效果不亚于华法林和达比加群,且安全性足够。在老年非瓣膜性AF患者中选择抗血栓治疗时,达比加群和氯吡格雷可被视为华法林可接受的替代药物。